A new kind of orphan drug?

A new kind of inheritance.

Drug development. Orphan drug windfalls?

New cystic fibrosis drug paves the way for orphan diseases.

A new kind of inner superefficient points.

Diazoxide--an orphan drug?

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes.

Head nodding in arteriopathic dementia--a new kind of tic?

Editorial: The HBV carrier--a new kind of leper?

Cell biology. A new kind of organic gardening.

Letter: "Orphan-drug" development - whose responsibility?

Rare lung disease and orphan drug development.

Judge upends 340B orphan drug exclusion.

Orphan Drug Act. Winners to keep all.

Editorial: Orphan GPCRs As Emerging Drug Targets.

Bush veto fuels orphan drug act uncertainties.

Creating the costliest orphan. The Orphan Drug Act in the development of Ceredase.

Research led by participants: a new social contract for a new kind of research.

New Financial and Research Models for Pediatric Orphan Drug Development - Focus on the NCATS TRND Program.

Five of a kind.

Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997-2012.

Three of a kind.

Successful development of an orphan drug for the pediatric population.

A different kind of merger.

Orphan diseases: state of the drug discovery art.

Suggest Documents

A new kind of inheritance.

Drug development. Orphan drug windfalls?

New cystic fibrosis drug paves the way for orphan diseases.

A new kind of inner superefficient points.

Diazoxide--an orphan drug?

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes.

Head nodding in arteriopathic dementia--a new kind of tic?

Editorial: The HBV carrier--a new kind of leper?

Cell biology. A new kind of organic gardening.

Letter: "Orphan-drug" development - whose responsibility?

Rare lung disease and orphan drug development.

Judge upends 340B orphan drug exclusion.

Orphan Drug Act. Winners to keep all.

Editorial: Orphan GPCRs As Emerging Drug Targets.

Bush veto fuels orphan drug act uncertainties.

Creating the costliest orphan. The Orphan Drug Act in the development of Ceredase.

Research led by participants: a new social contract for a new kind of research.

New Financial and Research Models for Pediatric Orphan Drug Development - Focus on the NCATS TRND Program.

Five of a kind.

Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997-2012.

Three of a kind.

Successful development of an orphan drug for the pediatric population.

A different kind of merger.

Orphan diseases: state of the drug discovery art.

A new kind of orphan drug?

Recommend Documents

Follow Us